Cannabidiol as potential treatment in refractory pediatric epilepsy

被引：18

作者：

Paolino, Maria Chiara ^{[1
]}

Ferretti, Alessandro ^{[1
]}

Papetti, Laura ^{[2
]}

Villa, Maria Pia ^{[1
]}

Parisi, Pasquale ^{[1
]}

机构：

[1] Univ Roma La Sapienza, Headache Paediat Ctr, Fac Med & Psychol,Chair Pediat,St Andrea Hosp, Paediat Sleep Disorders,Child Neurol,NESMOS Dept, Rome, Italy

[2] Univ Roma La Sapienza, Dept Pediat, Child Neurol Div, Piazzale Aldo Moro 5, I-00185 Rome, Italy

来源：

EXPERT REVIEW OF NEUROTHERAPEUTICS | 2016年 / 16卷 / 01期

关键词：

Cannabis; cannabidiol; CBD; epilepsy; refractory epilepsy in children; MITOCHONDRIAL-FUNCTION; PLANT CANNABINOIDS; MEDICAL MARIJUANA; SEIZURES; EXTRACTS; PHARMACOLOGY; SYMPTOMS; EFFICACY; DRUGS;

D O I：

10.1586/14737175.2016.1121098

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

In recent years there has been great scientific and public interest focused on the therapeutic potential of compounds derived from cannabis for the treatment of refractory epilepsy in children. From in vitro and in vivo studies on animal models, cannabidiol (CBD) appears to be a promising anticonvulsant drug with a favorable side-effect profile. In humans, CBD efficacy and safety is not supported by well-designed trials and its use has been described by anecdotal reports. It will be necessary to investigate CBD safety, pharmacokinetics and interaction with other anti-epileptic drugs (AEDs) alongside performing double-blinded placebo-controlled trials in order to obtain conclusive data on its efficacy and safety in children.

引用

页码：17 / 21

页数：5

共 50 条

[31] Decoding epilepsy treatment: A comparative evaluation contrasting cannabidiol pharmacokinetics in adult and paediatric populations
Osman, Mohamed
Khalil, Jamileh
El-Bahri, Mostafa
Mcdahrou, Jamal Swalah
Fahda, Reem
Mustafa, Reymin
Ooi, Arthur
Attayee, Marwa
Catanzariti, Rachelle
Pont, Lisa
Williams, Kylie
Yeung, Stewart
Dua, Kamal
De Rubis, Gabriele
Loebenberg, Raimar
CHEMICO-BIOLOGICAL INTERACTIONS, 2024, 394
[32] From an Alternative Medicine to a New Treatment for Refractory Epilepsies: Can Cannabidiol Follow the Same Path to Treat Neuropsychiatric Disorders?
Bitencourt, Rafael M.
Takahashi, Reinaldo N.
Carlini, Elisaldo A.
FRONTIERS IN PSYCHIATRY, 2021, 12 : 1 - 12
[33] A Review of Human Studies Assessing Cannabidiol's (CBD) Therapeutic Actions and Potential
White, C. Michael
JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (07) : 923 - 934
[34] Expectations and knowledge of cannabidiol therapy for childhood epilepsy - A German caregiver survey
Klotz, Kerstin Alexandra
Schoenberger, Jan
Nakamura, Lea
San Antonio-Arce, Victoria
Bast, Thomas
Wiemer-Kruel, Adelheid
Schubert-Bast, Susanne
Borggraefe, Ingo
Syrbe, Steffen
Jacobs, Julia
EPILEPSY & BEHAVIOR, 2020, 111
[35] Efficacy and Tolerance of Synthetic Cannabidiol for Treatment of Drug Resistant Epilepsy
Klotz, Kerstin A.
Grob, Daniel
Hirsch, Martin
Metternich, Birgitta
Schulze-Bonhage, Andreas
Jacobs, Julia
FRONTIERS IN NEUROLOGY, 2019, 10
[36] Cannabis for the Treatment of Epilepsy: an Update
Gaston, Tyler E.
Szaflarski, Jerzy P.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS, 2018, 18 (11)
[37] Ivermectin as an adjunct in the treatment of refractory epilepsy
Diazgranados-Sanchez, Jesus A.
Mejia-Fernandez, Jose L.
Chan-Guevara, Lissette S.
Valencia-Artunduaga, Mauricio H.
Costa, Jonathan L.
REVISTA DE NEUROLOGIA, 2017, 65 (07) : 303 - 310
[38] Cannabidiol (CBD) Alters the Functionality of Neutrophils (PMN). Implications in the Refractory Epilepsy Treatment
Gomez, Claudia Taborda
Lairion, Fabiana
Repetto, Marisa
Ettcheto, Miren
Merelli, Amalia
Lazarowski, Alberto
Auzmendi, Jeronimo
PHARMACEUTICALS, 2021, 14 (03)
[39] Cannabidiol: A Review of Clinical Efficacy and Safety in Epilepsy
Samanta, Debopam
PEDIATRIC NEUROLOGY, 2019, 96 : 24 - 29
[40] Update on Cannabidiol in Drug-Resistant Epilepsy
Singh, Akanksha
Madaan, Priyanka
Bansal, Dipika
INDIAN JOURNAL OF PEDIATRICS, 2025, 92 (01) : 61 - 69

← 1 2 3 4 5 →